Quality Measure (QM) Attainment in Overweight/Obese Patients with Type 2 Diabetes (T2DM) Treated with Canagliflozin (CANA) or Sitagliptin (SITA)

被引：0

|

作者：

Bailey, Robert

Vijapurkar, Ujjwala

Martin, Silas

Meininger, Gary

Rupnow, Marcia

机构：

来源：

DIABETES | 2014年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1047-P

引用

收藏

页码：A270 / A270

页数：1

相关论文

共 50 条

[1] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
Seufert, Jochen
Aggarwal, Naresh
Bailey, Robert
Cao, Anjun
Fung, Albert
Pfeifer, Michael
Alba, Maria
Rodbard, Helena W.
[J]. DIABETES, 2016, 65 : A308 - A308
[2] COMPOSITE QUALITY MEASURE (CQM) ATTAINMENT IN OVERWEIGHT/OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH CANAGLIFLOZIN 300 MG (CANA) OR SITAGLIPTIN 100 MG (SITA)
Bailey, R. A.
Vijapurkar, U.
Martin, S.
Meininger, G.
Rupnow, M. F.
[J]. VALUE IN HEALTH, 2014, 17 (03) : A239 - A239
[3] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
Lavalle Gonzalez, Fernando J.
Januszewicz, Andrzej
Davidson, Jaime
Qiu, Rose
Tong, Cindy
Meininger, Gary
[J]. DIABETES, 2013, 62 : A61 - A61
[4] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
Pititto, L.
Neslusan, C.
Teschemaker, A. R.
Johansen, P.
Willis, M.
Asano, E.
Puig, A.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
[5] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
Thompson, G.
Schroeder, M.
Neslusan, C.
Willis, M.
Johansen, P.
Teschemaker, A.
[J]. DIABETOLOGIA, 2014, 57 : S330 - S330
[6] WEIGHT- AND HEALTH-RELATED QUALITY OF LIFE (WRQOL AND HRQOL) WITH CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS (T2DM) ON BACKGROUND METFORMIN
Traina, S. B.
Ho, K. F.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A448 - A448
[7] Time Until Insulin Initiation for Canagliflozin (CANA) vs. Sitagliptin (SITA) in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK
Schroeder, Melanie
Chan, Edmond
Willis, Michael
Johansen, Pierre
Nilsson, Andreas
Schubert, Agata
Neslusan, Cheryl
[J]. DIABETES, 2016, 65 : A327 - A327
[8] SOURCES OF LONG-TERM QUALITY ADJUSTED LIFE YEAR (QALY) GAINS FOR CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
Willis, M.
Johansen, P.
Schroeder, M.
Thompson, G.
Girod, I
Neslusan, C.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A440 - A441
[9] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Pfeifer, Michael
Townsend, Raymond
Davies, Michael J.
Vijapurkar, Ujjwala
Ren, Jimmy
[J]. DIABETES, 2016, 65 : A303 - A303
[10] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Nyirjesy, Paul
Sobel, Jack
Fung, Albert
Gassmann-Mayer, Cristiana
Ways, Kirk
Usiskin, Keith
[J]. DIABETES, 2013, 62 : A276 - A276

← 1 2 3 4 5 →